D J Kempf
Overview
Explore the profile of D J Kempf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1474
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tong F, Zhang X, Kempf D, Yepes M, Connor-Stroud F, Zola S, et al.
AJNR Am J Neuroradiol
. 2015 Sep;
36(12):2354-9.
PMID: 26381560
Background And Purpose: Current nonhuman primate stroke models are limited by either stroke variability or survivability. A new nonhuman primate stroke model was developed by using endovascular trapping techniques to...
2.
Kempf D, ISAACSON J, King M, Brun S, Xu Y, Real K, et al.
J Virol
. 2001 Jul;
75(16):7462-9.
PMID: 11462018
The association of genotypic changes in human immunodeficiency virus (HIV) protease with reduced in vitro susceptibility to the new protease inhibitor lopinavir (previously ABT-378) was explored using a panel of...
3.
Sham H, Betebenner D, Herrin T, Kumar G, Saldivar A, Vasavanonda S, et al.
Bioorg Med Chem Lett
. 2001 May;
11(11):1351-3.
PMID: 11378352
The HIV protease inhibitor ABT-378 (Lopinavir) is metabolized rapidly and extensively by CYP-3A4 catalyzed oxidation. Three of the major metabolites identified were synthesized and their antiviral (HIV) activities determined.
4.
Cameron D, Japour A, Xu Y, Hsu A, Mellors J, Farthing C, et al.
AIDS
. 1999 Apr;
13(2):213-24.
PMID: 10202827
Objective: To evaluate the safety and antiretroviral activity of ritonavir (Norvir) and saquinavir (Invirase) combination therapy in patients with HIV infection. Design: A multicenter, randomized, open-label clinical trial. Setting: Seven...
5.
Chen X, Kempf D, Sham H, GREEN B, Molla A, Korneyeva M, et al.
Bioorg Med Chem Lett
. 1999 Feb;
8(24):3531-6.
PMID: 9934466
The 2-isopropyl thiazolyl group is a highly optimized P3 ligand for C2 symmetry-based HIV protease inhibitors, as exemplified in the drug ritonavir. Here we report that incorporation of this P3...
6.
Kumar G, Jayanti V, Lee R, Whittern D, Uchic J, Thomas S, et al.
Drug Metab Dispos
. 1999 Jan;
27(1):86-91.
PMID: 9884314
HIV protease inhibitor ABT-378 (ABT-378) was metabolized very extensively and rapidly by liver microsomes from mouse, rat, dog, monkey, and humans. The rates of NADPH-dependent metabolism of ABT-378 ranged from...
7.
Sham H, Kempf D, Molla A, Marsh K, Kumar G, Chen C, et al.
Antimicrob Agents Chemother
. 1998 Dec;
42(12):3218-24.
PMID: 9835517
The valine at position 82 (Val 82) in the active site of the human immunodeficiency virus (HIV) protease mutates in response to therapy with the protease inhibitor ritonavir. By using...
8.
Molla A, Vasavanonda S, Kumar G, Sham H, Johnson M, Grabowski B, et al.
Virology
. 1998 Oct;
250(2):255-62.
PMID: 9792836
The potency of therapeutic regimens containing human immunodeficiency virus (HIV) protease inhibitors is related to the ability to maintain concentrations of drug in the plasma of patients that are sufficient...
9.
Molla A, Granneman G, Sun E, Kempf D
Antiviral Res
. 1998 Oct;
39(1):1-23.
PMID: 9754946
No abstract available.
10.
Carrillo A, Stewart K, Sham H, Norbeck D, Kohlbrenner W, Leonard J, et al.
J Virol
. 1998 Aug;
72(9):7532-41.
PMID: 9696850
ABT-378, a new human immunodeficiency virus type 1 (HIV-1) protease inhibitor which is significantly more active than ritonavir in cell culture, is currently under investigation for the treatment of AIDS....